Developing a drug lead to target a new and abundant immune cell (2018)
The project aims to develop new drug-like compounds to block MAIT cell activation, which are the only immune T cells
that are activated by drug-like molecules. Like many immune cells, uncontrolled MAIT activation is linked to pathology
and disease. The study aims to redevelop two already approved drugs into new blockers of MAIT activation. The study
expects to shed new light on the chemical requirements for blocking MAIT activation and pathology, in order to aid in
developing a new drug-lead.